-
Asahi Kasei Moves to Fully Acquire Swedish Rare Disease Biopharma Calliditas in All-Cash Deal
•
Japan’s Asahi Kasei Corporation (TYO: 3407) has announced an all-cash offer to fully acquire the Swedish rare disease drug firm Calliditas Therapeutics AB (STO: CALTX). Both companies’ boards have approved the deal, with Asahi Kasei proposing to purchase all outstanding public shares of Calliditas at a price of SEK 416…
